Global Antibody Drug Conjugate Market Outlook - $3.45B By 2018
DUBLIN - Research and Markets (http://www.researchandmarkets.com/research/7h4p7l/global_antibody ) has announced the addition of the"Global Antibody Drug Conjugate Market Outlook 2018" report to their offering.
The ADC technology is not new; it dates back to the 90s. However, several issues such as specificity of the payload (drug), and poor conjugation of drug and antibody proved a setback. But, the past few years have witnessed ADCs make a glorious comeback. This can be attributed to the significant advancements that have been made in the field of linker technology as well as payload efficacy and specificity. There are currently two ADC products in the market, Adcetris and Kadcyla.
According to the report, Global Antibody Drug Conjugate Market Outlook 2018, backed by improved understanding and better technology, the ADC market is anticipated to reach US$ 3.45 Billion by 2018. The report analyzes the market for Adcetris and Kadcyla in detail. Market potential for these drugs has been estimated keeping in mind the fact that these drugs are being tested in clinical trials for various indications apart from the ones for which they are approved. These drugs will take some time in order to capture their entire potential market.
The report also provides an insight into the key ADCs that are currently in pipeline. At present, only one drug, Inotuzumab Ozogamicin is in late stage clinical trial. Apart from new drug candidates, previously approved drugs are also in late stage trials for other indications. Later in the report, strategic activities such as mergers, acquisitions and collaborations that have taken place over ADC have been provided. These activities are aimed at combining technologies and capabilities of other companies with inherent ones for the development of ADCs.